Psychiatry Research
Volume 190, Issue 2 , Pages 177-180 , 30 December 2011

Plasma asymmetric dimethylarginine (ADMA) concentrations in patients with first and multiple episode schizophrenia

  • Cemil Celik

      Affiliations

    • Gulhane Military Medical Academy, Department of Psychiatry, Ankara, Turkey
    • Corresponding Author InformationCorresponding author at: Department of Psychiatry, Gulhane Military Medical Academy, Etlik-06018, Ankara, Turkey. Tel.: +90 312 304 4501; fax: +90 312 304 4507.
    • ,
  • Tuncer Cayci

      Affiliations

    • Gulhane Military Medical Academy, Department of Medical Biochemistry, Ankara, Turkey
    • ,
  • Barbaros Ozdemir

      Affiliations

    • Gulhane Military Medical Academy, Department of Psychiatry, Ankara, Turkey
    • ,
  • Emin Ozgur Akgul

      Affiliations

    • Gulhane Military Medical Academy, Department of Medical Biochemistry, Ankara, Turkey
    • ,
  • Serkan Zincir

      Affiliations

    • Gulhane Military Medical Academy, Department of Psychiatry, Ankara, Turkey
    • ,
  • Adem Balikci

      Affiliations

    • Gulhane Military Medical Academy, Department of Psychiatry, Ankara, Turkey
    • ,
  • Ozcan Uzun

      Affiliations

    • Gulhane Military Medical Academy, Department of Psychiatry, Ankara, Turkey
    • ,
  • Halil Yaman

      Affiliations

    • Gulhane Military Medical Academy, Department of Medical Biochemistry, Ankara, Turkey

Received 4 April 2010 ,Revised 3 June 2011 ,Accepted 6 June 2011.

References 

  1. Andreasen NC. Methods for assessing positive and negative symptoms. Modern Problems of Pharmacopsychiatry. 1990;24:73–88
  2. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Archives of General Psychiatry. 1992;49:943–958
  3. Bełtowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacological Reports. 2006;58:159–178
  4. Böger RH, Bode-Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. Journal of the American College of Cardiology. 2000;36:2287–2295
  5. Brambilla P, Cerini R, Fabene PF, Andreone N, Rambaldelli G, Farace P, et al. Assessment of cerebral blood volume in schizophrenia: a magnetic resonance imaging study. Journal of Psychiatric Research. 2007;41:502–510
  6. Brown S, Inskip H, Barraclough B. Causes of excess mortality of schizophrenia. The British Journal of Psychiatry. 2000;177:212–217
  7. Casey DE, Hansen TE. Excessive morbidity and mortality in schizophrenia. In:  Meyer JM,  Nasrallah HA editor. Medical Illness and Schizophrenia. Washington (DC): American Psychiatric Publishing; 2003;
  8. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia. 2002;45:1609–1616
  9. Chen BM, Xia LW, Zhao RQ. Determination of NG, NG–dimethylarginine in human plasma by high-performance liquid chromatography. Journal of Chromatography B, Biomedical Sciences and Applications. 1997;692:467–471
  10. Das I, Khan NS, Puri BK, Hirsch SR. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neuroscience Letters. 1996;215:209–211
  11. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15–22
  12. Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. The American Journal of Psychiatry. 2008;165:1015–1023
  13. Erkoc S, Arkonac O, Ataklı C, Ozmen E. Negatif semptomlari degerlendirme olceginin guvenilirligi ve gecerliligi. Dusunen Adam. 1991;4:16–19
  14. Erkoc S, Arkonac O, Ataklı C, Ozmen E. Pozitif Semptomları Degerlendirme Olceginin guvenilirligi ve gecerliligi. Dusunen Adam. 1991;4:20–24
  15. Faraci FM, Brian JE. Nitric oxide and the cerebral circulation. Stroke. 1994;25:692–703
  16. Faraci FM, Brian JE, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. American Journal of Physiology. 1995;269:1522–1527
  17. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinical Version. Washington D.C.: American Psychiatric Press, Inc; 1997;
  18. Gonul AS, Kula M, Esel E, Tutus A, Tutus A, Sofuoglu SA. Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Research: Neuroimaging. 2003;123:199–205
  19. Gur RE, Skolnick BE, Gur RC, Caroff S, Rieger W, Obrist WD, et al. Brain function in psychiatric disorders. Regional cerebral blood flow in medicated schizophrenics. Archives of General Psychiatry. 1983;40:1250–1254
  20. Harris EC, Barraclough B. Excess mortality of mental disorder. The British Journal of Psychiatry. 1998;173:11–53
  21. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. The Journal of Clinical Psychiatry. 2003;64:575–579
  22. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. American Heart Journal. 2005;150:1115–1121
  23. Iwahashi K, Yoneyama H, Ohnishi T, Nakamura K, Miyatake R, Suwaki H, et al. Haloperidol inhibits neuronal nitric oxide synthase activity by preventing electron transfer. Neuropsychobiology. 1996;33:76–79
  24. Lukoff D, Nuechhtriein KH, Vertura J. Brief Psychiatric Rating Scale (BPRS) Version 3.0, Expanded Version. Los Angeles: UCLA Department of Psychiatry and Biobehaviioral Sciences, West Los Angeeles Medical Center; 1993;
  25. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. Journal of the American College of Cardiology. 2001;38:111–116
  26. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. British Journal of Pharmacology. 1996;119:1533–1540
  27. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor. A novel marker for atherosclerosis. Circulation. 1999;99:1141–1146
  28. Nel A, Harvey BH. Haloperidol-induced dyskinesia associated with striatal NO synthase inhibition: reversal with olanzapine. Behavioural Pharmacology. 2003;14:251–255
  29. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Canadian Journal of Psychiatry. 1991;36:239–245
  30. Ozkurkcugil A, Aydemir O, Yildiz M, Danaci AE, Koroglu E. DSM-IV eksen I bozukluklari icin yapilandirilmis klinik gorusmenin Turkceye uyarlanmasi ve guvenilirlik calismasi. Ilac ve Tedavi Dergisi. 1999;12:233–236
  31. Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Progress in Neurobiology. 2001;64:51–68
  32. Selley ML. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. Journal of Affective Disorders. 2004;80:249–256
  33. Soykan, C., 1989. Institutional differences, and case typicality as related to diagnosis system severity, prognosis and treatment. Yayimlanmamiş Yuksek Lisans Tezi. Ortadogu Teknik Universitesi. Ankara.
  34. Stefano GB. Biomedical Significance of Nitric Oxide. Warsaw-New York: Medical Science International Co. Ltd; 2003;
  35. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. Journal of the American Medical Association. 2002;287:1420–1426
  36. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127–2128
  37. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–575
  38. Vita A, Bressi S, Perani D, Invernizzi G, Giobbio GM, Dieci M, et al. High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. The American Journal of Psychiatry. 1995;152:876–882

PII: S0165-1781(11)00448-3

doi: 10.1016/j.psychres.2011.06.003

Psychiatry Research
Volume 190, Issue 2 , Pages 177-180 , 30 December 2011

Article Tools